您是记者吗？

了解 ALK

如有任何疑问，请直接联系 ALK 总部或任何全球办事处的媒体关系部。

The press releases in this press room contains information that is of general news value for the press, and available for journalists or media with a view to journalistic assessment and preparation before publication.

News

See all
  • Post date
    12/20/2024
    ALK – Financial calendar for the 2025 financial year
    Read more
  • Post date
    12/18/2024
    Positive results advance peanut tablet to phase II development
    Read more
  • Post date
    12/12/2024
    ACARIZAX® approved in Europe for treatment of young children
    Read more
  • Post date
    11/27/2024
    ALK’s pivotal phase 3 trial in children published in reputable scientific journal
    Read more
  • Post date
    11/14/2024
    Nine-month interim report (Q3) 2024 (unaudited)
    Read more
  • Post date
    11/09/2024
    ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
    Read more
  • Post date
    11/07/2024
    Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024
    Read more
  • Post date
    08/27/2024
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
    Read more
  • Post date
    08/22/2024
    Six-month interim report (Q2) 2024
    Read more

媒体关系

投资者关系

Per Plotnikof

企业传播、

投资者关系和战略规划

副总裁

电话：+45 2261 2525

电子邮件：PPIDK@alk.net

 

媒体关系

Jeppe Ilkjær

企业传播

媒体关系经理

电话：+45 3050 2014

电子邮件：Jeppe.Ilkjaer@alk.net

公司简介
快速了解过敏症免疫治疗市场中的领导者 ALK 的概况
关键财务数据
阅读 ALK 的最新财务业绩
欢迎记者朋友随时联系 ALK 的媒体关系团队。

图片

查找各种可供下载的图片。
Steen Riisgaard, CEO
下载图片
Production facilities, Hørsholm
下载图片
alk_produktion6_0
Production facilities, Hørsholm
下载图片
alk_produktion3_1
Production facilities, Hørsholm
下载图片
alk_produktion5
Production facilities, Hørsholm
下载图片
Family_website_0
ALK HQ, Hørsholm
下载图片
Last updated: 2016.11.14